When extubating a patient’s trachea, the difference between “minimal” and “shallow” block is important. We believe that a distinction between a deep and profound block is also justified, considering their significance for specific surgeries. We must emphasize that the proposal for introducing the profound block level into this list of definitions is not meant to encourage clinicians to achieve deeper block levels than they otherwise would. However, for some surgical procedures, such as intraocular, where even minor patient movements may be disastrous, and when diaphragmatic contractions must be prevented to avoid increases in intracranial pressure associated with tracheal suctioning, profound levels of block are recommended.3,9 Ultimately, these are decisions that each clinician must make based on individual clinical need. Our proposal merely fine-tunes the set of definitions of the various depths of neuromuscular block in an attempt to standardize the terminology. In addition, although profound block may be necessary in certain settings to prevent injury, the clinician cannot and must not assume that this technique is devoid of significant side effects. First, many clinicians do not have unrestricted access to sugammadex, while neuromuscular antagonism from profound degrees of block is ineffective with neostigmine. Second, the very surgeries that may require profound block (laparoscopic, robotic, eye, and airway surgery) have surgical closure times that are much shorter than traditional open abdominal procedures. Therefore, the depth of block at the time of neostigmine reversal may be deeper than of other surgeries, rendering patients at increased risk of residual neuromuscular block or recurrence of block (“recurarization”).
A second topic we believe needs to be addressed is the display of neuromuscular monitoring data over time. Older technology, such as the TOF-Watch (Organon, Ireland), allowed the user to download the intraoperative data onto an interfaced computer and display them in a trend format; these data included train-of-four ratio, baseline twitch height, train-of-four count, skin temperature, etc. Modern neuromuscular monitors should have a built-in trend function that can be reviewed by the clinician contemporaneously and should have the ability to be annotated by the user. We would welcome equipment with implemented algorithms that modify both the stimulation pattern and the interval time according to the result of the last measurement. Newer neuromuscular monitoring equipment such as the TOFscan (IdMed, Marseille, France), TetraGraph (Senzime BV, Uppsala, Sweden), and TOFcuff (RGB Medical, Madrid, Spain) display time and dosing-related courses of neuromuscular block with the main stimulation patterns of train-of-four ratio, train-of-four count, and post-tetanic counts. In some of these devices, a semiautomatic or even a fully automatic mode is already implemented.
However, this is still not sufficient. In an ideal system, during anesthesia and neuromuscular block induction, the device would measure TOF in short intervals (eg, every 20 seconds) as long as a train-of-four count is present. As soon as train-of-four count becomes 0 (which might be confirmed by a second measurement), the device should assess the post-tetanic counts. This would indicate that the neuromuscular block level has reached a deep block, where TOF stimulation does not yield positive values. Because of the more pronounced release of synaptic acetylcholine induced by the tetanic stimulation, the time interval after a post-tetanic count sequence should then automatically switch to a longer period (eg, 3 or 4 minutes) and avoid measurements during post-tetanic potentiation.10 In addition, before each post-tetanic count measurement, a TOF count of zero (train-of-four count = 0) should ensure that a tetanic stimulation is only delivered during deep or profound block. This sequence of train-of-four count = 0 followed by a post-tetanic count sequence should be repeated every 3 minutes until train-of-four count becomes positive (>0), in which case the sequence should automatically revert to train-of-four count every 20 seconds until train-of-four ratio >0.9. Users could set threshold limits for a desired neuromuscular block level, which would deliver a warning when a measurement is outside of the desired range.
Concerning the monitor screen, we suggest using intuitive symbols on a large screen, which enables an overview of a longer period, preferably with a variable time scale resolution. In the Figure, the consecutive display of the entire spectrum of neuromuscular block values is illustrated, as implemented to various degrees in the TetraGraph and in an experimental version of the TOFcuff software (Figure). In addition to these clear and self-explanatory symbols, we would like to include the option for the user to set a mark that indicates the moment when a repeated dose of neuromuscular block agent has been administered. This could be, for example, a small triangle at the upper screen margin, as depicted in the image. By viewing the neuromuscular blocking pattern and the times of drug dosing, the individual kinetics of a patient can be better understood, thus leading to better individualized neuromuscular blocking agent dosing.
A better delineation of the levels of intraoperative neuromuscular block, an improved trend display of the varying depths of intraoperative block with appropriate symbols to indicate important events, and the appearance on the market of new quantitative monitors are all significant events that should improve patient care.
Summarizing our proposals, we would modify Naguib scale by dividing the original deep block into profound block (post-tetanic counts = 1–3) and deep block (post-tetanic count ≥4 and train-of-four count = 0). We also suggest renumbering the levels with integers. New neuromuscular monitoring equipment may implement an automatic mode that adapts to the stimulation pattern and the time intervals to the measured values. Finally, a larger portion of the neuromuscular block course would be visible if displayed on a screen in a landscape orientation or as a module on the monitoring display, thus illustrating the timely context of dose and effect in a clear and intuitive fashion.
Peter Biro, MD, DESA.
Contribution: This author helped voice the necessity to present this topic and with the original idea for the frame and structure of the manuscript, and helped create the figure and write most of the text.
Conflicts of Interest: P. Biro has given recommendations for the configuration of the display in the TOFcuff monitor and is medical adviser of Guide In Medical, Nazareth, Israel, and has received travel allowances from Merck Sharp & Dohme AG, Switzerland.
Name: Georgina Paul, MD, MBChB.
Contribution: This author helped write parts of the text and completed the language editing and final check.
Conflicts of Interest: None.
Name: Albert Dahan, MD, PhD.
Contribution: This author helped discuss and solve the controversies and write the parts of the text.
Conflicts of Interest: A. Dahan has received consultancy/speaker fees from MSD Nederland BV as well as research funding for projects of his department at LUMC. In addition, he received consultancy fees from Medtronic and Medasense.
Name: Sorin J. Brull, MD, FCARCSI.
Contribution: This author helped discuss and solve the controversies in light of the cited paper by Naguib et al,8 and helped write parts of the text, and make a final check.
Conflicts of Interest: S. J. Brull has intellectual property assigned to Mayo Clinic (Rochester, MN); has received research funding from Merck & Co, Inc (funds to Mayo Clinic) and is a consultant for Merck & Co, Inc (Kenilworth, NJ); is a principal and shareholder in Senzime AB (publ) (Uppsala, Sweden); is a contributor to UpToDate (Wolters Kluwer, Waltham, MA); and a member of the Scientific Advisory Boards for ClearLine MD (Woburn, MA), The Doctors Company (Napa, CA), and NMD Pharma (Aarhus, Denmark).
This manuscript was handled by: Ken B. Johnson, MD.
1. Madsen MV, Scheppan S, Mørk E, Kissmeyer P, Rosenberg J, Gätke MR. Influence of deep neuromuscular block on the surgeonś assessment of surgical conditions during laparotomy: a randomized controlled double blinded trial with rocuronium and sugammadex. Br J Anaesth. 2017;119:435–442.
2. Özdemir-van Brunschot DMD, Braat AE, van der Jagt MFP, et al. Deep neuromuscular blockade improves surgical conditions during low-pressure pneumoperitoneum laparoscopic donor nephrectomy. Surg Endosc. 2018;32:245–251.
3. Fernando PU, Viby-Mogensen J, Bonsu AK, Tamilarasan A, Muchhal KK, Lambourne A. Relationship between posttetanic count and response to carinal stimulation during vecuronium-induced neuromuscular blockade. Acta Anaesthesiol Scand. 1987;31:593–596.
4. Martini CH, Boon M, Bevers RF, Aarts LP, Dahan A. Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. Br J Anaesth. 2014;112:498–505.
5. Torensma B, Martini CH, Boon M, et al. Deep neuromuscular block improves surgical conditions during bariatric surgery and reduces postoperative pain: a randomized double blind controlled trial. PLoS One. 2016;11:e0167907.
6. Bogani G, Uccella S, Cromi A, et al. Low vs standard pneumoperitoneum pressure during laparoscopic hysterectomy: prospective randomized trial. J Minim Invasive Gynecol. 2014;21:466–471.
7. Vijayaraghavan N, Sistla SC, Kundra P, et al. Comparison of standard-pressure and low-pressure pneumoperitoneum in laparoscopic cholecystectomy: a double blinded randomized controlled study. Surg Laparosc Endosc Percutan Tech. 2014;24:127–133.
8. Naguib M, Brull SJ, Kopman AF, et al. Consensus statement on perioperative use of neuromuscular monitoring. Anesth Analg. 2018;127:71–80.
9. Werba A, Klezl M, Schramm W, et al. The level of neuromuscular block needed to suppress diaphragmatic movement during tracheal suction in patients with raised intracranial pressure: a study with vecuronium and atracurium. Anaesthesia. 1993;48:301–303.
Copyright © 2019 International Anesthesia Research Society
10. Brull SJ, Silverman DG. Tetanus-induced changes in apparent recovery after bolus doses of atracurium or vecuronium. Anesthesiology. 1992;77:642–645.